These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 841390)

  • 21. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis.
    Vuilleumier N; Rossier MF; Chiappe A; Degoumois F; Dayer P; Mermillod B; Nicod L; Desmeules J; Hochstrasser D
    Eur J Clin Pharmacol; 2006 Jun; 62(6):423-9. PubMed ID: 16770646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver enzyme disturbances during isoniazid chemoprophylaxis in children.
    Beaudry PH; Brickman HF; Wise MB; MacDougall D
    Am Rev Respir Dis; 1974 Nov; 110(5):581-4. PubMed ID: 4429254
    [No Abstract]   [Full Text] [Related]  

  • 23. Isoniazid preventive therapy in areas of high isoniazid resistance.
    Sterling TR; Brehm WT; Frieden TR
    Arch Intern Med; 1995 Aug 7-21; 155(15):1622-8. PubMed ID: 7618985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis.
    Warrington RJ; McPhilips-Feener S; Rutherford WJ
    Clin Allergy; 1982 May; 12(3):217-22. PubMed ID: 7105389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current changes in the recommendations for INH preventive treatment of tuberculous infection in Alabama.
    J Med Assoc State Ala; 1974 Sep; 44(3):140-1. PubMed ID: 4419724
    [No Abstract]   [Full Text] [Related]  

  • 26. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
    Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isoniazid chemoprophylaxis. Association with detection and incidence of liver toxicity.
    Byrd RB; Horn BR; Griggs GA; Solomon DA
    Arch Intern Med; 1977 Sep; 137(9):1130-3. PubMed ID: 332099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of rifampicin and isoniazid on liver function.
    Lal S; Singhal SN; Burley DM; Crossley G
    Br Med J; 1972 Jan; 1(5793):148-50. PubMed ID: 5007842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How safe is isoniazid?
    Thompson JE
    Med J Aust; 1978 Feb; 1(3):165-9. PubMed ID: 651734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemoprophylaxis of pulmonary tuberculosis. Current recommendations and controversies.
    Johnson JR
    Postgrad Med; 1983 Sep; 74(3):64-9. PubMed ID: 6889211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pattern of adverse drug reactions experienced by tuberculosis patients in a tertiary care teaching hospital in Western Nepal.
    P V K; Palaian S; Ojha P; P R S
    Pak J Pharm Sci; 2008 Jan; 21(1):51-6. PubMed ID: 18166520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Preventive therapy in middle-aged and elderly persons selected from the population-based screening by mass miniature radiography--methodological aspect and adverse reactions].
    Ohmori M; Wada M; Nishii K; Nakazono T; Masuyama H; Yoshiyama T; Inaba K; Itoh K; Uchimura K; Saegusa M; Mitarai S; Kimura M; Shimouchi A
    Kekkaku; 2002 Oct; 77(10):647-58. PubMed ID: 12440139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis.
    Mitchell JR; Zimmerman HJ; Ishak KG; Thorgeirsson UP; Timbrell JA; Snodgrass WR; Nelson SD
    Ann Intern Med; 1976 Feb; 84(2):181-92. PubMed ID: 766682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical hepatotoxicity of isoniazid in children.
    Stein MT; Liang D
    Pediatrics; 1979 Oct; 64(4):499-505. PubMed ID: 492816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
    Fresard I; Bridevaux PO; Rochat T; Janssens JP
    Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.
    Sadaphal P; Astemborski J; Graham NM; Sheely L; Bonds M; Madison A; Vlahov D; Thomas DL; Sterling TR
    Clin Infect Dis; 2001 Nov; 33(10):1687-91. PubMed ID: 11641824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for isoniazid (NIH)-induced liver dysfunction.
    Dickinson DS; Bailey WC; Hirschowitz BI; Soong SJ; Eidus L; Hodgkin MM
    J Clin Gastroenterol; 1981 Sep; 3(3):271-9. PubMed ID: 7288121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isoniazid preventive therapy: Retrospect and prospect.
    Dash LA; Comstock GW; Flynn JP
    Am Rev Respir Dis; 1980 Jun; 121(6):1039-44. PubMed ID: 7416591
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluation of isoniazid-associated hepatitis by immunological tests.
    Warrington RJ; Tse KS; Gorski BA; Schwenk R; Sehon AH
    Clin Exp Immunol; 1978 Apr; 32(1):97-104. PubMed ID: 668195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients.
    Sotsuka T; Sasaki Y; Hirai S; Yamagishi F; Ueno K
    In Vivo; 2011; 25(5):803-12. PubMed ID: 21753138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.